STOCK TITAN

Anixa Biosciences Inc (ANIX) CEO purchases 3,000 shares at $3.73

(Neutral)
(Positive)
Form Type
4

Rhea-AI Filing Summary

Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 3,000 shares of Common Stock on July 24, 2026 at $3.73 per share in an open-market or private transaction. Following this trade, his directly held position increased to 643,812 shares of Anixa Biosciences Inc common stock.

Positive

  • None.

Negative

  • None.
Insider KUMAR AMIT
Role Chief Executive Officer
Bought 3,000 shs ($11K)
Type Security Shares Price Value
Purchase Common Stock 3,000 $3.73 $11K
Holdings After Transaction: Common Stock — 643,812 shares (Direct)
Shares purchased 3,000 shares Common Stock acquired on July 24, 2026
Purchase price per share $3.73 per share Price for the 3,000-share Common Stock purchase
Shares held after transaction 643,812 shares Direct Common Stock ownership by Amit Kumar following the trade
Net buy shares in filing 3,000 shares Net buying reported across all transactions in this Form 4
Number of buy transactions 1 Single non-derivative open-market or private purchase reported
Common Stock financial
"security title listed as Common Stock in the reported transaction"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
non-derivative financial
"transaction_type is described as non-derivative for this security"
open market financial
"transaction code description states purchase in open market or private transaction"
An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.
direct financial
"ownership_type is recorded as direct for the acquired shares"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did ANIX report for CEO Amit Kumar?

Anixa Biosciences Inc reported that CEO Amit Kumar purchased 3,000 shares of Common Stock on July 24, 2026 at $3.73 per share, increasing his directly held stake to 643,812 shares after the transaction.

Was the ANIX CEO’s July 24, 2026 trade a buy or a sell?

The Form 4 shows a buy transaction. Amit Kumar executed a purchase of 3,000 shares of Anixa Biosciences Inc Common Stock, coded as a "P" open-market or private purchase, with no sales reported in this filing.

At what price did the ANIX CEO buy shares on July 24, 2026?

The reported purchase price was $3.73 per share. Amit Kumar acquired 3,000 shares of Anixa Biosciences Inc Common Stock at this per-share price in a transaction classified as a non-derivative open-market or private purchase.

How many ANIX shares does CEO Amit Kumar hold after this Form 4 transaction?

After the reported purchase, Amit Kumar directly holds 643,812 shares of Anixa Biosciences Inc Common Stock. This reflects his updated direct ownership position following the 3,000-share acquisition on July 24, 2026.

Did the ANIX CEO’s July 2026 trade occur under a Rule 10b5-1 plan?

The Form 4’s Rule 10b5-1 checkbox is not marked, so this 3,000-share purchase is not affirmed as being executed pursuant to a Rule 10b5-1 trading plan in this filing.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KUMAR AMIT

(Last)(First)(Middle)
C/O ANIXA BIOSCIENCES, INC.
3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)
SAN JOSE CALIFORNIA 95118

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/24/2026P3,000A$3.73643,812D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
/s/ Amit Kumar07/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)